Sol-Gel Technologies (SLGL) Shares Outstanding (2016 - 2026)
Sol-Gel Technologies' (SLGL) quarterly Shares Outstanding (Entity) came in at $2.8 million in Q1 2026, up 1.84% year-on-year from $2.8 million in Q1 2025, and up 1.82% on a QoQ basis from $2.8 million in Q4 2025.
Sol-Gel Technologies (SLGL) Shares Outstanding (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Shares Outstanding (Entity) data on file, last reported at $2.8 million in Q1 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 1.84% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 1.84% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, changed 0.01% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $2.8 million, up from $2.8 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for SLGL reached as high as $2.8 million in Q1 2026 and fell as low as $2.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $2.7 million across 5 years, with a median of $2.8 million in 2023.
- Across the five-year window, Shares Outstanding (Entity) grew 20.44% in 2023 and changed 0.0% in 2024, its largest moves.
- Year by year, Shares Outstanding (Entity) stood at $2.3 million in 2022, then advanced by 20.44% to $2.8 million in 2023, then changed by 0.0% to $2.8 million in 2024, then increased by 0.01% to $2.8 million in 2025, then advanced by 1.82% to $2.8 million in 2026.
- Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 47.82 Bn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 118.76 Bn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.44 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 62.06 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 198.10 Mn |
| 10 | Sol-Gel Technologies | 234.04 Mn | 223.91 Mn | - | 2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 2.79 Mn |
| Jun 30, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | 2.79 Mn |
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Dec 31, 2023 | 2.71 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 2.77 Mn |
| Mar 31, 2023 | 2.49 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 2.31 Mn |
| Jun 30, 2022 | 2.31 Mn |
| Mar 31, 2022 | 2.31 Mn |
| Dec 31, 2021 | 2.31 Mn |
| Sep 30, 2021 | 2.31 Mn |
| Jun 30, 2021 | 2.30 Mn |